QUIA — QUIA PHARMA AB (publ) Share Price
Last trade - 00:00- SEK35.69m
- SEK35.68m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.18 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -175.28% | ||
| Return on Equity | -183.07% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 1.86 | 0.22 | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
QUIA PHARMA AB (publ) is a pharmaceutical development company based on a patented drug delivery based on a platform technology, Uni-Qleaver, which helps to release an active pharmaceutical ingredient in a controlled manner over time. The Company develops improved and patentable forms of drugs under development or already approved by drug authorities. These forms of drugs are based on the Company's technology platform. In addition, the Company offers global sales of omega-3, astaxin and collagen through Amazon. The Company's technology platform can be used for the development of drug substances that have promising biological effects but challenging pharmacological properties as well as improved versions of already approved drugs called biobetters.
Directors
- Steen Kroyer CHM
- Marcus Bosson CEO
- Erik Magnusson CFO
- Jouni Tukiainen CEX (46)
- Cecilia Kemi COO
- Jonas Jarvius DRC (48)
- Christian Krog-Jensen DRC
- Marek Kwiatowski DRC
- Lars Linzander DRC (63)
- Johan von Kantzow DRC (46)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 18th, 2004
- Public Since
- June 21st, 2005
- No. of Employees
- 8
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 3,366,573,200
- Address
- Uppsala Business Park, UPPSALA, 754 50
- Web
- https://www.quiapeg.com/
- Phone
- +46 87780006
- Auditors
- BDO Malardalen AB
Upcoming Events for QUIA
Similar to QUIA
Biogaia AB
OMX Nordic Exchange Stockholm
BoneSupport Holding AB
OMX Nordic Exchange Stockholm
Camurus AB
OMX Nordic Exchange Stockholm
Cinclus Pharma Holding publ AB
OMX Nordic Exchange Stockholm
Corline Biomedical AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 22:49 UTC, shares in QUIA PHARMA AB (publ) are trading at SEK0.01. This share price information is delayed by 15 minutes.
Shares in QUIA PHARMA AB (publ) last closed at SEK0.01 and the price had moved by -82.32% over the past 365 days. In terms of relative price strength the QUIA PHARMA AB (publ) share price has underperformed the FTSE Global All Cap Index by -82.76% over the past year.
There is no consensus recommendation for this security.
Find out moreQUIA PHARMA AB (publ) does not currently pay a dividend.
QUIA PHARMA AB (publ) does not currently pay a dividend.
QUIA PHARMA AB (publ) does not currently pay a dividend.
To buy shares in QUIA PHARMA AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK0.01, shares in QUIA PHARMA AB (publ) had a market capitalisation of SEK35.69m.
Here are the trading details for QUIA PHARMA AB (publ):
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: QUIA
Based on an overall assessment of its quality, value and momentum QUIA PHARMA AB (publ) is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like QUIA PHARMA AB (publ). Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -47.88%.
As of the last closing price of SEK0.01, shares in QUIA PHARMA AB (publ) were trading -37.61% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The QUIA PHARMA AB (publ) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
QUIA PHARMA AB (publ)'s management team is headed by:
- Steen Kroyer - CHM
- Marcus Bosson - CEO
- Erik Magnusson - CFO
- Jouni Tukiainen - CEX
- Cecilia Kemi - COO
- Jonas Jarvius - DRC
- Christian Krog-Jensen - DRC
- Marek Kwiatowski - DRC
- Lars Linzander - DRC
- Johan von Kantzow - DRC